Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Sun Pharma Announces Expiration of Subsequent Offering Period

September 29, 2010 7:32 am | by Bio-Medicine.Org | News | Comments

MUMBAI, India, Sept. 29 /- Sun Pharmaceutical Industries Ltd. (Sun) (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced the expiration of the subsequent offering period to the tender offer by Sun's subsidiary Alkaloida Chemical Company Exclusive Group Ltd...

TOPICS:

Growing Nanowires horizontally yields new benefit: 'Nano-LEDs'

September 29, 2010 4:37 am | by I-Micronews | News | Comments

While refining their novel method for making nanoscale wires, chemists at the National Institute of Standards and Technology (NIST) discovered an unexpected bonus?a new way to create nanowires that produce light similar to that from light-emitting diodes (LEDs).

AccessClosure Announces Distribution Agreement for Radial Compression Band

September 29, 2010 4:34 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Sept. 29 /- AccessClosure, Inc., the market leader in extravascular closure devices, announced today an exclusive agreement with Benrikal Services to distribute the Bengal Radial Compression Band in the United States.  The Bengal, uniquely designed for...

TOPICS:
Advertisement

NINDS awards new Udall Centers for Parkinson's Disease Research

September 29, 2010 4:33 am | by EurekAlert | News | Comments

(NIH/National Institute of Neurological Disorders and Stroke) The NINDS has established two new sites as part of the Morris K. Udall Centers of Excellence in Parkinson's Disease Research: Emory University in Atlanta and the Feinstein Institute for Medical Research in Manhasset, N.Y.

TOPICS:

ItN Nanovation announces partnership with ThyssenKrupp Xervon Energy covering Nanocomp PP

September 29, 2010 2:33 am | by I-Micronews | News | Comments

Exclusive cooperation agreement for advanced nanoceramic technology used in power plants

REACH register to ensure traceability of nanomaterials

September 29, 2010 2:33 am | by I-Micronews | News | Comments

Ahead of a regulatory review next year, the Belgian EU Presidency is proposing to create a specific register for nanomaterials under the bloc's REACH chemicals regulation and wants to make it mandatory to label their presence in consumer products.

Doctors need to help patients prepare better for health decisions

September 28, 2010 11:32 pm | by EurekAlert | News | Comments

(University of Michigan) Twelve years ago, then 28-year-old graduate student Brian Zikmund-Fisher was forced into the toughest choice of his life: Die from a blood disorder within a few years or endure a bone marrow transplant that could cure him or kill him in weeks.

TOPICS:

<i>From the Bench: </i>Alfama shows carbon monoxide can be therapeutic, if they can deliver it

September 28, 2010 8:34 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

Alfama Inc. sees carbon monoxide as a therapy for a significant number of medical conditions, including liver failure, rheumatoid arthritis, heart attack and gastric ulcers. The trick is in delivering CO to the disease site without causing the problems that most people associate with the gas.

TOPICS:
Advertisement

Nanotechnology Brings Personalized Therapy One Step Closer to Reality

September 28, 2010 4:32 pm | by AACR | News | Comments

DENVER — A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.

TOPICS:

c-Met May Be a Biomarker for Metastatic Hepatocellular Carcinoma

September 28, 2010 3:31 pm | by AACR | News | Comments

Tweet • c-Met activation linked with poor prognosis. • c-Met was highly overexpressed in metastatic liver cancer cells. DENVER — Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have...

TOPICS:

Regence to stop selling child-only health plans

September 28, 2010 2:45 pm | by RACHEL LA CORTE - Associated Press Writer - Associated Press | News | Comments

Regence BlueShield announced Tuesday that it will stop selling new child-only individual insurance policies by the end of this week.The move comes less than a week after several provisions of the federal health care overhaul went into effect, including one that prevents insurance companies from...

Women and Infants provides fertility preservation for childhood cancer survivors

September 28, 2010 1:35 pm | by EurekAlert | News | Comments

(Women & Infants Hospital) Unfortunately, the aggressive treatments for cancer may often render a child infertile. The likelihood that this will occur depends on the child's age, type of cancer and treatment plan. The Program for Fertility Preservation at Women & Infants Hospital...

TOPICS:

African-Americans Equally Likely to Benefit from Erlotinib and Other Targeted Lung Cancer Therapy

September 28, 2010 1:34 pm | by AACR | News | Comments

DENVER — African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

TOPICS:

Novel Test Following Prostate Surgery Could Detect Cancer Recurrence Earlier

September 28, 2010 1:33 pm | by AACR | News | Comments

DENVER — A new test could reliably detect early increases in prostate specific antigen (PSA) levels — a biomarker commonly used to measure the recurrence of prostate cancer — in men who have undergone prostate cancer-treating surgery. Earlier detection of these rising levels would allow...

TOPICS:

Draft Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Herpes Simplex Virus Types 1 and 2 Serological Assays

September 28, 2010 1:31 pm | by U.S. Food & Drug Administration | News | Comments

This special controls guidance document was developed to support the reclassification of the herpes simplex virus types 1 and 2 (HSV 1 and 2) serological assays into class II. HSV serological assays are devices that consist of antigens and antisera...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading